ASX:TLX
Telix Pharmaceuticals Ltd
Investment Summary
The fund managers believe that Telix Pharmaceuticals Ltd is demonstrating strong potential, particularly with its recent share price rally driven by favourable survival data in treating radiographic castration-resistant prostate cancer. In their opinion, this marks a significant advancement in Telix's therapeutic pipeline, which is described as catalyst rich. Despite the positive momentum, they have opted to reduce their position size to lock in profits after a strong rally. Additionally, the fund managers highlight Telix's drug Illuccix, which has seen growth and market share gains, suggesting that the upcoming US approval and launch of TLX-250x could serve as a major driver for future share price increases, particularly due to expected high clinician adoption in kidney cancer diagnostics.
Commentary From The Managers
Milford Asset Management
31 May 2024
$18.15
- Telix Pharmaceuticals experienced a share price increase of 20.6%.
- The rally was driven by favourable survival data regarding its treatment for radiographic castration-resistant prostate cancer.
- This result represents a positive step toward advancing its therapeutic pipeline.
- The pipeline is noted to be catalyst rich, suggesting ongoing potential for growth.
- In light of the strong share price rally over the past two months, Milford Asset Management has reduced its position size and locked in profits.
Milford Asset Management
31 Jan 2024
$11.50
- Milford Asset Management notes a significant increase in Telix Pharmaceuticals Ltd of +14.1% following a recent trading update.
- The drug Illuccix has shown growth in line with expectations and has gained market share.
- Key potential driver for future growth includes the expected US approval and launch of TLX-250x in the second half of the year.
- Forecasts suggest a high adoption rate among clinicians for TLX-250x in the diagnosis of kidney cancer.
- Milford Asset Management continues to monitor these developments closely.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.